Update on medical therapies of nasopharyngeal carcinomas;Actualités des traitements médicaux des cancers du nasopharynx

Bulletin du Cancer

Volumn 97, Issue 4, 2010, Pages 417-426

  Boussen, Hamouda ^a,c   Bouaouina, Noureddine ^b,c   Daldoul, Olfa ^a   Benna, Farouk ^a,c   Gritli, Said ^a   Ladgham, Abderrahman ^a  

^a SALAH AZAIEZ INSTITUTE   (Tunisia)

^b FARHAT HACHED HOSPITAL   (Tunisia)

^c Arome Association de Radiotherapie et d'Oncologie de la Mediterranee   (Tunisia)

Author keywords

Carcinoma; Chemotherapy; Nasopharyngeal; Prognosis; Radiotherapy; Survival; TNM; Undifferentiated

Indexed keywords

BLEOMYCIN; CISPLATIN; EPIRUBICIN; FLUOROURACIL; UFT; ANTINEOPLASTIC AGENT;

CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; HIGH RISK PATIENT; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; PROGNOSIS; REVIEW; UNDIFFERENTIATED CARCINOMA; ADOLESCENT; ARTICLE; CANCER STAGING; CARCINOMA; CHILD; HUMAN; INFANT; LYMPH NODE METASTASIS; METHODOLOGY; MULTIMODALITY CANCER THERAPY; NASOPHARYNX TUMOR; NEWBORN; ONSET AGE; PATHOLOGY; PRESCHOOL CHILD; RADIATION DOSE FRACTIONATION; TREATMENT OUTCOME; TUMOR VOLUME;

ADOLESCENT; AGE OF ONSET; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; HUMANS; INFANT; INFANT, NEWBORN; LYMPHATIC METASTASIS; NASOPHARYNGEAL NEOPLASMS; NEOPLASM STAGING; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 77952131569     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2010.1091     Document Type: Article

References (72)

1. Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet 2005; 365: 2041-2054
2. Fandi A, Altun M, Azli N, Armand JP, Cvitkovic E. Nasopharyngeal cancer: epidemiology, staging and treatment. Semin Oncol 1994; 21: 382-397
3. Boussen H, Bouaouina N, Mokni-Baizig N, Gamoudi A, Chouchane L, Benna F, et al. Carcinomes du nasopharynx. Données actuelles. Pathologie Biologie 2005; 53: 45-51.
4. Lee AW, Sze WM, Au JS, Leung SF, Chua DT, Zee BC, et al. Treatment results for nasopharyngeal carcinoma in the modern area: the Hong Kong experience. Int J Radiat Oncol Biol Phys 2005; 61: 1107-1116
5. Yu MC, Yuan JM. Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol 2002; 12: 421-429
6. Parkin DM, Wheelan S, Ferlay J, Raymond L. Young J eds. Cancer incidence in five continents. IARC 1997; 143: 814-815
7. Chan ATC, Teo PML, Huang DP. Pathogenesis and treatment of nasopharyngeal carcinoma. Semin Oncol 2004; 31: 784-801.
8. Kumar MB, Lu JJ, Loh KS, Chong LMJ, Soo R, Goh BC, et al. Tailoring distant metastatic imaging for patients with clinically localized undifferentiated nasopharyngeal carcinoma. Int J Radiat Oncology Biol Phys 2004; 58: 688-693 (Pubitemid 38221122)
9. Chang JT, Chan SC, Yen TC, Liao CT, Lin CY, Lin KJ, et al. Nasopharyngeal carcinoma staging by (18)F-fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys 2005; 62: 501-507
10. Jmal A, Boussen H, Abdennebi M, Gara S, Harzallah L, Gritli S, et al. Cyfra 21 dans les carcinomes indifférenciés du nasopharynx en Tunisie. Bull Cancer 2004; 91: 369-372
11. Chan KH, Gu YL, Ng PS, Seto WH, Sham JS. EBV specific antibody-based and DNA-based assays in serologic diagnosis of nasopharyngeal carcinoma. Int J Cancer 2003; 105: 706-709
12. Sobin LH, Wittekind CH. "Pharynx". In : TNM Classification of Malignant Tumors. UICC Publication. New York: Wiley-Liss, 2002, p. 27-35.
13. Law CK, Foo W, Lau WH. In-depth evaluation of the AJCC/ UICC 1997 staging system of nasopharyngeal carcinoma: prognostic homogeneity and proposed refinements. Int J Radiat Oncol Biol Phys 2003; 56: 413-426
14. Liao XB, Mao YP, Liu LZ, Tang LL, Sun Y, Wang Y, et al. How does magnetic resonance imaging influence staging according to AJCC staging system for nasopharyngeal carcinoma compared with computed tomography? Int J Radiat Oncol Biol Phys 2008; 72: 1368-1377
15. Jmal A, Boussen H, Gara S, Ghanem A, Abaza H, Gara S, et al. Le cancer du nasopharynx de l'enfant en Tunisie: étude rétrospective épidémiologique, clinique et biologique à propos de 48 cas. Bull Cancer 2005; 92: 977-981 (Pubitemid 43001116)
16. Chua DT, Sham JS, Kwong DL, Au GK. Treatment outcome after radiotherapy alone for patients with Stage I-II nasopharyngeal carcinoma. Cancer 2003; 98: 74-80. (Pubitemid 36741128)
17. Marks JE, Bedwinek JM, Lee F, Purdy JA, Perez CA. Dose-response analysis for nasopharyngeal carcinoma: an historical perspective. Cancer 1982; 50: 1042-1050 (Pubitemid 12062879)
18. Teo PML, Yu P, Lee WY, et al. Significant prognostic factors after primary radiotherapy in 903 non-disseminated nasopharyngeal carcinoma evaluated by computed tomography. Int J Radiat Oncol Biol Phys 1996; 36: 291-304. (Pubitemid 26359452)
19. Wasserman TH, Brizel DM, Henke M, Monnier A, Eschwege F, Sauer R, et al. Influence of intravenous amifostine on xerostomia, tumor control and survival after radiotherapy for head and neck cancer: 2-year follow-up of a prospective randomized phase III trial. Int J Radiat Oncol Biol Phys 2005; 63: 985-990 (Pubitemid 41505273)
20. Wang CC. Accelerated hyperfractionation radiation therapy for carcinoma of the nasopharynx. Techniques and results. Cancer 1989; 63: 2461-2467
21. Lin JC, Chen KY, Jan JS, Hsu CY. Partially hyperfractionated accelerated radiotherapy and concurrent chemotherapy for advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1996; 36: 1127-1136 (Pubitemid 27014499)
22. Kam MK, Leung SF, Zee B, Chau RM, Suen JJ, Mo F, et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 2007; 25: 4873-4879 (Pubitemid 350220416)
23. Lee N, Xia P, Quivey JM. Intensity modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the USCF experience. Int J Radiat Oncol Biol Phys 2002; 53: 12-22. (Pubitemid 34465802)
24. Wolden SL, Chen WC, Pfister DG. Intensity-modulated radiation therapy for nasopharynx-cancer: update of the memorial Sloan- Kettering experience. Int J Radiat Oncol Biol Phys 2006; 64: 57-62. (Pubitemid 41831209)
25. Hunt MA, Zelefsky MJ, Wolden S. Treatment planning and delivery of intensity-modulated radiotherapy for primary nasopharynx cancer. Int J Radiat Oncol Biol Phys 2001; 49: 623-632 (Pubitemid 32112190)
26. Sultanem K, Shu HK, Xia P. Three-dimensional intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys 2000; 48: 711-722
27. Mc Millan AS, Pow EH, Kwong DL. Preservation of quality of life after intensity-modulated radiotherapy for early-satge nasopharyngeal carcinoma: results of prospective longitudinal study. Head Neck, 2006; 28: 712-722
28. Ng T, Richards GM, Emery RS, Ho G, Yung R, Cheng A, et al. Customized conformal high-dose brachytherapy boost for limited-volume nasopharyngeal cancer. Int J Radiat Oncology Biol Phys 2005; 61: 754-761 (Pubitemid 40247970)
29. Taheri-Kadkhoda Z, Pettersson N, Björk-Eriksson T, Johansson KA. Superiority of intensity-modulated radiotherapy over three-dimensional conformal radiotherapy combined with brachytherapy in nasopharyngeal carcinoma: a planning study. Br J Radiol 2008; 81: 397-405. (Pubitemid 351743854)
30. Faivre S, Janot F, Armand JP. Optimal management of nasopharyngeal carcinoma. Curr Opin Oncol 2004; 16: 231-235
31. Ma BB, Chan AT. Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma. Cancer 2005; 103: 22-31. (Pubitemid 39665453)
32. Rossi A, Molinari R, Boracchi P, Del Vecchio M, Marubini E, Nava M, et al. Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: results of a 4-year multicenter randomized study. J Clin Oncol 1988; 6: 1401-1410 (Pubitemid 19089028)
33. Prasad U, Wahid MI, Jalaludin MA, Abdullah BJ, Paramsothy M, Abdul-Kareem S. Long-term survival of nasopharyngeal carcinoma patients treated with adjuvant chemotherapy subsequent to conventional radical radiotherapy. Int J Radiat Oncol Biol Phys 2002; 53: 648-655 (Pubitemid 34626503)
34. Baujat B, Audry H, Bourhis J, Chan AT, Onat H, Chua DT, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 2006; 64: 47-56. (Pubitemid 41831208)
35. Chan AT, Teo PM, Leung TW. A prospective randomized study of adjunctive to definitive to radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1995; 33: 569-577
36. Chua DT, Ma J, Sham JS, Mai HQ, Choy DT, Hong MH, et al. Long term survival after cisplatin-based chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. J Clin Oncol 2005; 23: 1118-1124 (Pubitemid 46202267)
37. International Nasopharynx Cancer Study Group. VUMCA I trial: preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin-epirubicin-bleomycin) plus radiotherapy vs radiotherapy alone in stage IV(V>N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. Int J Radiat Oncol Biol Phys 1996; 36: 1005-1012
38. Hareyama M, Sakata K, Shirato H. A prospective randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma. Cancer 2002; 94: 2217-2223 (Pubitemid 34411980)
39. Al-Sarraf M, Le Blanc M, Giri PG, Fu KK, Cooper J, Vuong T, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998; 16: 1310-1317 (Pubitemid 28175745)
40. Chan AT, Ngan R, Teo P. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Nat Cancer Inst 2005; 97: 536-539 (Pubitemid 40590436)
41. Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS, Wang WY. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall andprogression-free survival. J Clin Oncol 2003; 21: 631-637
42. Kwong DL, Sham JS, Au GK, Chua DT, Kwong PW, Cheng AC, et al. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. J Clin Oncol 2004; 22: 2643-2653
43. Wee AW, Lau WH, Tung SY. Prospective randomised study on therapeutic gain achieved by addition of chemotherapy for T1-4N2 nasopharyngeal carcinoma: NPC-9901 trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol 2005; 23: 6966-6975 (Pubitemid 46264015)
44. Wee J, Tan EH, Tai BC, Wong HB, Leong SS, Tan T, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 2005; 23: 6730-6738 (Pubitemid 46190268)
45. Oh JL, Vokes EE, Kies MS, Mittal BB, Witt ME, Weichselbaum RR, et al. Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer. Ann Oncol 2003; 14: 564-569 (Pubitemid 41295084)
46. Lin JC, Jan JS, Hsu CY, Jiang RS, Wang WY. Outpatient weekly neoadjuvant chemotherapy followed by radiotherapy for advanced nasopharyngeal carcinoma: high complete response and low toxicity rates. Br J Cancer 2003; 27: 187-194
47. Ma J, Mai HQ, Hong MH, Min HQ, Mao ZD, Cui NJ, et al. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol 2001; 19: 1350-1357 (Pubitemid 32202540)
48. Qin D, Hu Y, Yan J, Xu GZ, Cai WM. Analysis of 1379 patients with nasopharyngeal carcinoma treated by radiation. Cancer 1988; 61: 1117-1124 (Pubitemid 18078600)
49. Yee D, Hanson J, Lau H, Siever J, Gluck S. Treatment of nasopharyngeal carcinoma in the modern era: analysis of outcomes and toxicity from a single center in a nonendemic area. Cancer J 2006; 12: 147-154
50. Leung TW, Tung SW, Sze WK. Treatment results of 1070 patients with nasopharyngeal carcinoma: an analysis of survival and failure patterns. Head Neck 2005; 27: 555-565
51. Boussen H, Cvitkovic E, Wendling JL, Azli N, Bachouchi M, Mahjoubi R, et al. Chemotherapy of metastatic and/or recurrent undifferentiated nasopharyngeal carcinoma with cisplatin, bleomycin and fuorouracil. J Clin Oncol 1991; 9: 1675-1681
52. Wang CC, Chang JY, Liu TW. Phase II study of gemcitabine plus vinorelbine in the treatment of cisplatine-resistant nasopharyngeal carcinoma. Head Neck 2006; 28: 74-80. (Pubitemid 43099638)
53. Fandi A, Bachouchi M, Azli N, Taamma A, Boussen H, Wibault P, et al. Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type. J Clin Oncol 2000; 18: 1324-1330 (Pubitemid 30159852)
54. Lee AWM, Poon YF, Foo W. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976- 1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys 1992; 23: 261-270
55. Chan AT, Hsu MM, Goh BC, Hui EP, Liu TW. Multicenter phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 2005; 20: 3568-3576 (Pubitemid 46243502)
56. Lee JT, Ko CY. Has survival improved for nasopharyngeal carcinoma in the United States. Otolaryngol Hed Neck Surg 2005; 132: 3003-3008
57. Lee AW, Foo W, Mang O, Sze WM, Chappell R, Lau WH, et al. Changing epidemiology of nasopharyngeal carcinoma in Hong Kong over a 20-year period (1980-1999): an encouraging reduction in both incidence and mortality. Int J Cancer 2003; 103: 680-685
58. Liu MT, Hsieh CY, Chang TH, Lin JP, Huang CC, Wang AY. Prognostic factors affecting the outcome of nasopharyngeal carcinoma. Jpn J Clin Oncol 2003; 33: 501-508 (Pubitemid 43115242)
59. Yeh SA, Tang Y, Lui CC. Treatment outcomes and late complications of 849 patients with nasopharyngeal carcinoma treated with radiotherapy alone. Int J Radiat Oncol Biol Phys 2005; 62: 672-679 (Pubitemid 40779753)
60. Hui EP, Poon TC, Teo PM, Mo F, Zee B, Leung SF, et al. A prospective study of pre-treatment cell kinetics and clinical outcome in nasopharyngeal carcinoma. Radiother Oncol 2003; 69: 53-62. (Pubitemid 37346189)
61. Farias TP, Dias FL, Lima RA, Kligerman J, De Sa GM, Barbosa MM, et al. Prognostic factors and outcome for nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 2003; 129 : 794-799 (Pubitemid 36858970)
62. Leung SF, Chan AT, Zee B, Ma B, Chan LY, Johnson PJ, et al. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of post-therapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type. Cancer 2003; 98: 288-291 (Pubitemid 36828452)
63. Chang CC, Chen MK, Liu MT, Wu HK, Hwang KL. Effect of primary tumour volumes in early T-stage nasopharyngeal carcinoma. J Otolaryngol 2003; 32: 87-92.
64. Shen C, Lu JJ, Gu Y, Zhu G, Hu C, He S. Prognostic impact of primary tumor volume in patients with nasopharyngeal carcinoma treated by definitive radiation therapy. Laryngoscope, 2008; 118: 1206-1210
65. Toh CK, Heng D, Ong YK, Leong SS, Wee J, Tan EH. Validation of a new prognostic index score for disseminated nasopharyngeal carcinoma. Br J Cancer 2005; 92: 1382-1387 (Pubitemid 40705003)
66. Yuan Y, Zhou X, Song J, Qiu X, Li J, Ye L, et al. Expression and clinical significance of epidermal growth factor receptor and type 1 insulin-like growth factor receptor in nasopharyngeal carcinoma. Ann Otol Rhinol Laryngol 2008; 117: 192-200. (Pubitemid 351415354)
67. Foote RL, Weidner N, Harris J, Hammond E, Lewis JE, Vuong T, et al. Evaluation of tumor angiogenesis measured with microvessel density as a prognostic indicator in nasopharyngeal carcinoma: results of RTOG 9505. Int J Radiat Oncol Biol Phys 2005; 61: 745-753 (Pubitemid 40247969)
68. Lee JT, Ko CY. Has survival improved for nasopharyngeal carcinoma in the United States. Otolaryngol Hed Neck Surg 2005; 132: 3003-3008
69. Gharbi MK, Gritli S, Boussen H, Benna F, Ben Abdallah M, El May A, et al. Retrospective study of 2010 cases of nasopharyngeal carcinoma seen at the insitute Salah Azaiz from 1969 to 1988. Proceedings ASCO 1996; 15: 197 (American society of Clinical Oncology).
70. Leung TW, Tung SW, Sze WK. Treatment results of 1070 patients with nasopharyngeal carcinoma: an analysis of survival and failure patterns. Head Neck 2005; 27: 555-565
71. Yeh SA, Tang Y, Lui CC. Treatment outcomes and late complications of 849 patients with nasopharyngeal carcinoma treated with radiotherapy alone. Int J Radiat Oncol Biol Phys 2005; 62: 672-679 (Pubitemid 40779753)
72. Lee AW, Lau WH, Tung SY. Prospective randomised study on therapeutic gain achieved by addition of chemotherapy for T1- 4N2 nasopharyngeal carcinoma: NPC-9901 trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol 2005; 23: 6966-6975 (Pubitemid 46264015)